701P - Bimonthly regimen of high dose leucovorin, infusional 5-fluorouracil, docetaxel and cisplatin (modified DCF) in advanced gastric adenocarcinoma

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anti-Cancer Agents & Biologic Therapy
Gastric Cancer
Presenter ILKAY Unek
Authors I.T. Unek1, T. Akman1, I. Oztop2, O.U. Unal1, T. Salman1, A.U. Yilmaz1
  • 2Department Of Internal Medicine, Oncology Institute, 35440 - izmir/TR


The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is an effective but highly toxic regimen for the treatment of advanced gastric cancer. In the palliative chemotherapy of tumors, it is necessary to improve the drug safety while ensuring efficacy. We developed a modified DCF regimen with goal to minimize toxicity without compromising efficacy. In our study, seventy patients with advanced gastric cancer were treated. Each 2-week cycle consisted of docetaxel (60 mg/m2), cisplatin (50 mg/m2), 5-fluorouracil (400 mg/m2) IV bolus and 5-fluorouracil (2400 mg/m2) IV over 46 hours plus leucovorin (400 mg/m2) IV over 2 hours. The median progression-free survival and overall survival were 9.0 months (95% CI, 7.1-10.9) and 10.8 months (95% CI, 7.4-14.2), respectively; the 1-year and 2-year survival rates were 46.3% and 18.4%, respectively. Twenty-nine (41.4%) partial responses, 19 (27.1%) stable disease, and 22 (31.4%) progression of disease were observed. Grade 3-4 toxicities included neutropenia (37.1%), febrile neutropenia (15.7%), thrombocytopenia (10.0%), anemia (8.6%), nausea and vomiting (10.0%), stomatitis (5.7%), infection (8.6%), diarrhea (2.9%). In summary, our results show that a modified DCF regimen may have tolerable toxicities and be an effective and convenient palliative treatment of advanced gastric cancer.


All authors have declared no conflicts of interest.